MMP25: A Potential Drug Target for Cell Signaling and Tissue Repair

Target Name: MMP25

NCBI ID: G64386

MMP25

MMP25: A Potential Drug Target for Cell Signaling and Tissue Repair

MMP25, also known as matrix-type 6 matrix metalloproteinase (MMP25), is a protein that plays a crucial role in cell signaling and tissue repair. It is a 25 kDa transmembrane protein that is expressed in various tissues, including the uterus, pancreas, and blood vessels. MMP25 has been implicated in a wide range of physiological processes, including cell migration, invasion, and extracellular matrix (ECM) formation.

MMP25 has also been shown to be a potential drug target and biomarker. Several studies have demonstrated that inhibition of MMP25 can lead to therapeutic benefits in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, MMP25 has emerged as a promising target for small molecule inhibitors.

One of the key reasons for the potential of MMP25 as a drug target is its involvement in ECM formation. ECM is a complex structure that is essential for maintaining tissue architecture and providing mechanical support. MMP25 is a key enzyme in the breakdown of ECM, which allows cells to move and invade through the ECM.

In cancer, ECM formation is a critical step in the cell's journey to invade and metastasize. MMP25 has been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. Therefore, inhibition of MMP25 has been shown to be an effective way to treat cancer.

Another potential mechanism by which MMP25 can be targeted as a drug is its role in cell signaling. MMP25 has been shown to be involved in several signaling pathways that are important for cell survival and growth. For example, MMP25 has been shown to be involved in the TGF-β pathway, which is a critical pathway for cell signaling and growth.

MMP25 has also been shown to be involved in the FGF pathway, which is involved in cell proliferation and survival. In addition, MMP25 has been shown to be involved in the Wnt pathway, which is involved in cell growth and development.

In neurodegenerative diseases, MMP25 has been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, inhibition of MMP25 has been shown to be an effective way to treat neurodegenerative diseases.

In addition to its role in cell signaling, MMP25 has also been shown to be involved in ECM formation. As mentioned earlier, MMP25 is involved in the breakdown of ECM, which allows cells to move and invade through the ECM. This is important for the development and progression of cancer, as well as the development and progression of neurodegenerative diseases.

Finally, MMP25 has also been shown to be involved in the regulation of cellular immortalization. immortalization refers to the process by which cells become immortal, meaning that they can continue to divide without the normal checks and balances that control cell growth. MMP25 has been shown to play a role in the regulation of cellular immortalization, which is important for the development and progression of cancer.

In conclusion, MMP25 is a protein that plays a crucial role in cell signaling and tissue repair. It is a 25 kDa transmembrane protein that is expressed in various tissues, including the uterus, pancreas, and blood vessels. MMP25 has been implicated in a wide range of physiological processes, including cell migration, invasion, and extracellular matrix (ECM) formation. In addition, MMP25 has

Protein Name: Matrix Metallopeptidase 25

Functions: May activate progelatinase A

The "MMP25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMP25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets